GlycoMimetics is a biopharmaceutical company designing and developing small molecule therapeutics to treat various cancers.
Industries BiotechnologyHealth CareTherapeuticsDiversity Spotlight (US Headquarters Only) Women FoundedHeadquarters Regions Washington DC Metro Area, East Coast, Southern US Founded Date 2003 Founders John Magnani, Rachel King Operating Status Active Last Funding Type Post-IPO Equity
Stock Symbol NASDAQ:GLYC Company Type For Profit
Contact Email webmaster@glycomimetics.com Phone Number 2402431207
GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound
for the treatment or prevention of infections caused by pseudomonas aeruginosa. The company was founded in 2003 and is based in Gaithersburg, Maryland.